3 US Low Volatility Stocks For Steadier Healthcare Earnings

With the S&P 500 trading on a forward P/E of 21.1 versus a 10 year average of 18.9, rich valuations, heavy AI expectations and a concentrated technology sector are leaving many investors wondering where to find steadier ground. This is where low volatility stocks can become interesting, especially when inflation is still above the Fed’s 2% target and further rate moves are on the table. Below, three stocks from a low volatility screener, all exposed to these market drivers in different ways, are revealed and assessed to help you think more clearly about risk as well as return potential.

Overview: Boston Scientific is a large medical device company that makes minimally invasive tools doctors use to diagnose and treat heart rhythm problems, digestive and urological conditions, chronic pain, and certain cancers. Its portfolio spans everything from cardiac defibrillators and pacemakers to single use endoscopes and neuromodulation systems used in everyday hospital and specialist procedures worldwide.

Operations: Boston Scientific generates about US$6.9b from its MedSurg segment and US$13.7b from Cardiovascular, with revenue spread across the U.S. (US$13.2b), EMEA (US$3.5b), Asia Pacific (US$3.2b), and Latin America and Canada (US$0.7b).

Market Cap: US$67.3b

Boston Scientific stands out in a market dominated by AI heavy tech stocks because it sits in a large cap healthcare niche where demand is tied to essential procedures rather than hype cycles. The company has been expanding higher value therapies like FARAPULSE and WATCHMAN and adding assets such as Penumbra. Together these broaden its reach and can support margins even if headline growth cools. At the same time, product recalls, reimbursement pressure and slower growth in the WatchMAN franchise show that execution and regulatory risk are real and can weigh on sentiment. For investors looking for relatively steadier earnings, a global footprint and exposure to procedure growth instead of AI optimism, Boston Scientific offers a different way to think about risk and reward in a richly valued market.

Boston Scientific’s expanding higher value therapies and global footprint could be masking what really matters for long term returns, so it is worth reviewing the analysis report for Boston Scientific to see the crucial detail investors often miss.

Overview: ResMed is a medical technology company that makes devices and cloud software to diagnose, treat, and manage sleep apnea and other breathing disorders, while also providing software used by home health, hospice, and senior care providers. Its products range from at home sleep testing tools and connected CPAP machines to electronic health record and billing systems that help care providers run their operations.

Operations: ResMed generates about US$4.9b from Sleep and Breathing Health and US$670.9m from Residential Care Software.

Market Cap: US$27.2b

ResMed sits in a part of healthcare where demand is tied to chronic sleep and respiratory conditions, which can look appealing when investors are worried about expensive, AI heavy markets and index concentration. Its mix of devices and connected software, plus acquisitions like Noctrix Health, is aimed at deepening its role across the sleep health journey while supporting margins. At the same time, investors need to weigh real risks, including pressure from reimbursement changes, new competitors in sleep apnea and alternative treatments such as GLP 1 drugs, as well as concerns flagged in recent analyst downgrades. Taken together, Boston Scientific and ResMed illustrate how low volatility healthcare stocks can offer different risk trade offs than the broader tech led indices.

ResMed’s sleep and respiratory reach, along with its software arm, could be setting up a very different growth story to headline AI stocks, but the real twist sits in the analyst forecasts for ResMed that most investors overlook.

Overview: Ensign Group is a healthcare services company that runs skilled nursing, senior living and rehabilitation facilities across 17 U.S. states, while also owning a separate real estate arm that leases post acute care properties to healthcare operators. Alongside facility based care, it provides ancillary services such as mobile diagnostics, dialysis, respiratory therapy and long term care pharmacy to patients in facilities or at home.

Operations: Ensign Group generates about US$5.0b from Skilled Services, US$242.7m from All Other services and US$134.6m from Standard Bearer, with intercompany eliminations of US$148.4m and total reported revenue of roughly US$5.3b almost entirely from the United States.

Market Cap: US$8.9b

Ensign Group catches the eye in a market where many investors are questioning richly valued, AI heavy stocks because its core business of skilled nursing and post acute care is tied to ongoing healthcare needs rather than tech cycles. Revenue is around US$5.3b, earnings growth has been solid in recent years, and analysts expect it to keep growing. Yet the stock trades only slightly below some fair value estimates and on a higher P/E than many healthcare peers, which raises questions about how much good news is already reflected in the price. On one side are an active acquisition pipeline, buybacks and a long dividend record. On the other side are allegations from short sellers and reliance on external borrowing. Together, these factors suggest the company may warrant a closer look at quality, growth durability and risk.

Ensign Group’s acquisition engine, dividend track record and post acute focus hint at a story investors may be underestimating, and the real question sits inside the analyst forecasts for Ensign Group that could change how you view the stock.

The three low volatility stocks covered here are only a starting point, with the full Low Volatility Stocks screener surfacing 24 more large companies with equally compelling risk reward narratives that do not rely on AI hype or narrow sector bets. Use Simply Wall St to identify and analyze the specific catalysts, balance sheet strength, and earnings profiles that matter to you, so you can focus on the highest conviction opportunities within this low volatility theme.

Take Control of Your Investment Journey

If ResMed or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value the ideal entry point.
Once you’ve made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates.
Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives.
By uncovering hidden catalysts and risks early, you’ll accelerate your decision-making and stay one step ahead of the market.

Seeking Alternatives Beyond Low Volatility?

Fresh stock ideas can move from quiet to breakout quickly, and the best entry points often pass while everyone is caught looking elsewhere, so act now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com